Simplify Asset Management Inc. Cuts Stake in Sanofi (NASDAQ:SNY)

Simplify Asset Management Inc. trimmed its holdings in shares of Sanofi (NASDAQ:SNY - Free Report) by 80.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 40,387 shares of the company's stock after selling 163,756 shares during the period. Simplify Asset Management Inc.'s holdings in Sanofi were worth $1,948,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of SNY. Boston Partners increased its stake in shares of Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company's stock worth $260,607,000 after buying an additional 2,501,073 shares during the period. Franklin Resources Inc. increased its position in shares of Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company's stock valued at $208,106,000 after acquiring an additional 395,744 shares during the period. Magnetar Financial LLC raised its stake in shares of Sanofi by 104.3% during the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company's stock valued at $161,103,000 after acquiring an additional 1,705,148 shares during the last quarter. Natixis Advisors LLC raised its stake in shares of Sanofi by 1.2% during the fourth quarter. Natixis Advisors LLC now owns 2,910,021 shares of the company's stock valued at $140,350,000 after acquiring an additional 35,828 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Sanofi during the fourth quarter worth about $135,933,000. 14.04% of the stock is owned by institutional investors.

Remove Ads

Sanofi Stock Up 0.8 %

Shares of NASDAQ:SNY traded up $0.41 during midday trading on Thursday, reaching $54.91. The company's stock had a trading volume of 1,320,100 shares, compared to its average volume of 2,262,514. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The firm has a 50 day moving average of $55.03 and a 200-day moving average of $52.85. The firm has a market capitalization of $139.35 billion, a P/E ratio of 22.05, a PEG ratio of 1.01 and a beta of 0.58. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, research analysts anticipate that Sanofi will post 4.36 earnings per share for the current year.

Analysts Set New Price Targets

SNY has been the topic of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. The Goldman Sachs Group started coverage on shares of Sanofi in a research note on Friday, March 21st. They set a "neutral" rating and a $65.00 target price on the stock. Finally, StockNews.com downgraded shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $62.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.